5 Best Life Sciences Penny Stocks to Buy

2. AbCellera Biologics Inc. (NASDAQ:ABCL)

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 8 Best Life Sciences Penny Stocks to Buy.

On March 23, AbCellera Biologics Inc. (NASDAQ:ABCL) presented at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum, with Senior Director of Strategic Finance and Investor Relations Martin Hogan covering the company’s drug discovery platform and pipeline development. Hogan provided an interesting insight into the story of about 13 years, which began with investing in technologies for almost a decade for developing capabilities from target nominations through manufacturing of the drug product, all related to antibodies as therapeutic agents.

The speaker argued that the differentiated technology approach taken in drug discovery, along with all the investments made since, in addition to the more than 100 programs that the company was involved in discovering drugs, resulted in establishing the capability of tackling the hardest targets accessible using antibody-based therapies. Not only does this create a downstream stake in programs conducted by the company for their partners, but it also creates a portfolio of internal programs. Recently, the company progressed one of its drugs into Phase II of its clinical study, effectively becoming an integrated mid- to late-stage biotech firm.

According to Hogan, there were four key factors considered during the assessment of each program’s feasibility: derisked science, high unmet medical need and commercial viability, competitive advantage, and a sound path for developing the candidate drugs.

AbCellera Biologics Inc. (NASDAQ:ABCL) is involved in the research and development of antibody-based medications to address unmet healthcare needs in the U.S. It has two medicine candidates: ABCL635, which is in Phase 2 of clinical trials, and ABCL575, which is in Phase 1. Additionally, it has partnership agreements with firms, including those with Eli Lilly and Company and AbbVie Inc.